


T2



February 9, 1984

Mr. R.J. Everett, Chief Material Rad. Protection
Nuclear Regulatory Commission
611 Ryan Plaza Drive Suite 1000
Arlington, TX 76011

Control #60142

Dear Mr. Everett:

Thank you for your consideration of our license for byproduct material usage. In response to the four items that you requested in your letter of January 16, the following information should clarify these questions:

- #1. Dr. Patrick Haney is the only physician at this time that will be using byproduct materials under our license. You should already be in receipt of the necessary information on Dr. Haney's preceptor statements, etc.
- #2. We will be including an ALARA program and a signed copy of this appendix is attached.
- #3. Item #21 showing 250 mCi for xenon-133 is correct.
- #4. All of our iodine-131 use is in capsule form, therefore eliminating the necessity of hoods, personnel bioassay, and contamination surveys. The largest dose that we will be administering would be 50 millicuries, and the use and handling is in appendix K. The routine doses for therapy would run between 5 and 10 mCi, and our normal yearly patient total would be approximately 5 for this type of therapy.

If I may further clarify any of these items or answer any other questions, please let me know.

Sincerely,

Darrell E. Wilson
Executive Director

DEW/mls

8602110451 851129
REG4 LIC30 PDR
35-17926-02

60142

MS-12